Search

for
Search:

Research

5 / 1000+ results

research Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?

7 citations , April 2017 in “Health Economics, Policy and Law”

This review analyzes current patent trends in personalized medicine, suggesting they often privilege the pharmaceutical industry without adequately demonstrating overall public benefit.

Purpose-Limited Pharmaceutical Product Claims Under the Revised European Patent Convention: A Camouflaged Attack on Generic Substitution?

research Purpose-limited pharmaceutical product claims under the revised European Patent Convention: A camouflaged attack on generic substitution?

3 citations , January 2010 in “Ghent University Academic Bibliography (Ghent University)”

This article reviews the impact of the 2000 revision of the European Patent Convention on drug patent protection and raises concerns about its effects on generic substitution and healthcare professionals.

Generic Competition And Pharmaceutical Patent Strategies: A Sequel

research Generic competition and pharma patent strategies - a sequel

October 2008 in “Journal of Intellectual Property Law & Practice”

The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.

research Medical treatment methods, medical indication claims and patentability: A quest into the rationale of the exclusion and patentability in the context of the future of personalised medicine

2 citations , January 2016 in “UvA-DARE (University of Amsterdam)”

This review explores the unclear rationale behind excluding medical treatment methods from patentability and the complexities of allowing medical indication patents, offering potential solutions but reporting no new results.

research Court of Appeal can overrule itself to follow the EPO: UK adopts EPO stance on second medical use claims

July 2008 in “Journal of Intellectual Property Law & Practice”

This ruling by the UK Court of Appeal allows patents for pharmaceuticals based on new dosing regimens and can override previous decisions to align with European Patent Office practices.

View more "pharmaceutical patents" in research →

Community Join

5 / 545 results

community Brief update clascoterone phase 3 - Breezula

in Research/Science 4 upvotes 2 years ago

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.

in Research/Science 73 upvotes 11 months ago

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.

25 upvotes 1 year ago

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march

30 upvotes 5 months ago

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

community Parents found my finasteride stash and are forcing me to dispose all of it

164 upvotes 3 years ago

A 21-year-old has been using finasteride for nearly a year with positive results for hair loss. His parents found his stash, misunderstood the risks, and are forcing him to dispose of it, leading him to seek advice on handling the situation.

View more "pharmaceutical patents" in community →

Learn

6 / 801 results

learn Baricitinib

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

learn Dexpanthenol

precursor of vitamin B5 with hair stimulating effects

learn Saw Palmetto

a natural and far less effective alternative to Finasteride

learn Hair Multiplication

extract, clone, and reinsert your own hair cells

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

View more "pharmaceutical patents" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →